Microsoft word - explanatory_note_ 2010_list_final_en_rev_web
September 19, 2009 2010 Prohibited List Summary of Major Modifications
The introductory sentence on the use of drugs limited to medically justified
The reference to Specified Substances has been amended in accordance with
SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF- COMPETITION)
S1: Anabolic Agents
The International Nonproprietary Name (INN) for methyltrienolone has been
Comment S1.1b, including revisions, is addressed in another WADA document
S2. Peptide Hormones, Growth Factors and Related Substances
In order to better define the substances within this category, the title has been
revised to “Peptide Hormones, Growth Factors and Related Substances”.
To reflect the growing number of new erythropoeisis-stimulating substances
available, methoxy polyethylene glycol-epoetin beta (CERA) has been added as
The issue of growth factors enhancing certain functions was addressed in more
detail. Additional examples of growth factors affecting muscle, tendon or
ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching [e.g. Platelet-derived Growth
Factor (PDGF), Fibroblast Growth Factors (FGFs), Vascular-Endothelial Growth Factor (VEGF), Hepatocyte Growth Factor (HGF)] were included.
The status of Platelet-derived preparations (e.g. Platelet Rich Plasma, “blood
Comment S2 is addressed in another WADA document (Technical Document
The use of salbutamol and salmeterol by inhalation no longer requires a TUE but
It is specified that the maximum dose for the controlled pharmacokinetic study
cannot exceed the maximum therapeutic dose for inhaled salbutamol (1600 µg/day).
Two examples of aromatase inhibitors, androstene-3,6,17 trione (6-oxo) and
androsta-1,4,6-triene-3,17-dione (androstatrienedione) have been added in
view of their wide availability as components of nutritional supplements.
The status of glycerol (oral and intravenous) as a plasma expander was clarified
The non-prohibited status of pamabrom was clarified because it is a weak
diuretic largely available as a combined over-the-counter medication for pre-menstrual/menstrual symptoms.
M1. Enhancement of Oxygen Transfer
Supplemental oxygen is no longer prohibited.
Proteases have been added as an example of sample adulteration.
The status of intravenous infusions has been reviewed and now reads:
“Intravenous infusions are prohibited except for those legitimately received in
the course of hospital admissions or clinical investigations.”
For clarification purposes the gene doping definition was reworded and split into
SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION
Three stimulants, namely benfluorex, prenylamine, both known to metabolize to
non-specified stimulants (amphetamine or norfenfluramine) as well as
methylhexaneamine, a non-therapeutic substance, were added to the closed list of non-specified stimulants.
Until 2003, the stimulant pseudoephedrine had been prohibited in sports with a
threshold of 25 μg/mL. Pseudoephedrine has been included in the Monitoring
Program since 2004. Results from the Monitoring Program over the past 5 years have shown a sustained increase in urinary concentrations of
pseudoephedrine. In addition, there is clear evidence of abuse in some sports and some regions which show clusters of samples with high pseudoephedrine
concentrations many times in excess of concentrations normally found. Furthermore, the available literature demonstrates scientific proof of its performance enhancing effects at certain doses. Therefore, the List Committee
has reintroduced pseudoephedrine as a specified stimulant in the 2010 Prohibited List at a urinary threshold of 150 µg/mL based on the results from
controlled excretion studies as well as the literature. Given the wide availability of pseudoephedrine-containing medicines, WADA recommends that the
reintroduction of pseudoephedrine is supported by active information/education campaign by all stakeholders.
Although pseudoephedrine is now prohibited, it will remain in the Monitoring
Program for urinary concentrations below 150 µg/mL.
It is clarified that synthetic cannabinoids are covered by this section.
SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1. Alcohol and P2. Beta-blockers
As the responsibility for testing in the sports of Boules and Archery has been
transferred from the International Paralympic Committee (IPC) to the World Bowling Federation and the International Archery Federation (FITA),
respectively, references to the IPC have been deleted.
XXI Congreso de la Sociedad Valenciana de Patología Digestiva Valencia, 30 de noviembre y 1 de diciembre de 2007SUMARIOVolumen 30, extraordinario 3, Noviembre 2007 Junta Directiva Sociedad Valenciana de Patología Digestiva Comité científico Avance de Programa COMUNICACIONES PRESENTADAS EN EL CONGRESO Comunicaciones orales 1 Pósters 12 Índice de autores 17 XXI Cong
XIX FIGO WORLD CONGRESS OF GYNECOLOGY AND OBSTETRICS INDUSTRY-SPONSORED SYMPOSIA Monday, 5 October 2009 13h00-14h15 Ballroom East (CTICC) Contraception and Beyond: Evidence-based Indications for LNG-IUS 1. Wider Use of Intrauterine Contraception - David Grimes 2. The LNG-IUS in Heavy Menstrual Bleeding: First-line Treatment Based on Comprehensive Clinical Data - Anita Nelson3. S